Co-Diagnostics Inc Announces Positive Results from Co-Primers™ Technology in Multiplex Tests for SNP Detection
February 28 2018 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that ongoing research and development activities of
the Company’s Co-Primer™ platform technology has yielded positive
results in demonstrating the capabilities of Co-Primers in
multiplex tests for SNP detection.
The Company will utilize its proprietary design software and
patent-pending Co-Primer technology to provide molecular testing
solutions for use by customers. These include enterprise clients,
specifically those interested in testing for targeted gene
sequences in multiplexed reactions, in the research, infectious
diseases, agricultural, ranching, and food production industries,
as well as large clinical laboratories. The above industries rely
upon molecular testing for a variety of applications, ranging from
testing for harmful bacteria or vector-borne diseases, liquid
biopsy applications, and developing in-house diagnostics to assist
with infectious disease testing. Customers in the latter category
would be able to use the technology to design and verify their own
laboratory developed tests (“LDTs”).
Co-Diagnostics CEO Dwight Egan commented: “The unique properties
of Co-Primers make them ideally suited for a variety of
applications where sensitivity is the key to optimal results,
including multiplexing several targets, enhanced SNP detection, and
rare allele enrichment for next-gen sequencing. Co-Diagnostics is
excited to provide these groundbreaking technical advances to the
worldwide molecular testing market.”
About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that has developed
and intends to manufacture and sell reagents used for diagnostic
tests that function via the detection and/or analysis of nucleic
acid molecules (DNA or RNA), and to sell diagnostic equipment from
other manufacturers as self-contained lab systems.
Forward-Looking Statements:This press release contains
forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180228005559/en/
Company Contact:Co-DiagnosticsAndrew BensonCo-Diagnostics
Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024